RegMIC’s 10th annual meeting covers organoid-specific standards

WINSTON-SALEM, NC – December 16, 2025 – In anticipation of breakthroughs in organoid technologies that will shape the next generation of biomanufacturing, the Regenerative Manufacturing Innovation Consortium focused its 10^th annual meeting around organoid and body-on-a-chip systems.

The RegMIC conference, held December 2 and 3 in Charlotte, N.C., covered organoid-specific standards from cells to manufacturing to shipping and logistics.

Since its first meeting in 2014, the Regenerative Manufacturing Innovation Consortium has been instrumental in creating the standards that will accelerate the production of technologies. The consortium took what it learned at its first conference and published those takeaways in the Stem Cells Translational Medicine Journal. That white paper, titled “Manufacturing Road Map for Tissue Engineering and Regenerative Medicine Technologies,” was the first to outline the needs and challenges in producing regenerative medicine technologies.  

Every year, RegMIC has built upon that initial road map. In 2018, the consortium published an updated white paper, focusing on an industry-driven road map to define what is needed to scale industrial manufacturing.

“Given how RegMIC has been working on standards for the manufacturing of organoids for over a decade and how organoid and body-on-a-chip technologies have advanced, we knew that this was the prime opportunity to assemble multiple stakeholders to solidify a roadmap for organoid-specific standards,” said Joshua Hunsberger, PhD, Chief Technology Officer of the Regenerative Medicine Development Organization (ReMDO).

The conference brought together expert speakers from across industry, academia, and federal agencies, including the U.S. Food and Drug Administration, the Biomedical Advanced Research and Development Authority, and NASA.

“The speakers and attendees left the meeting energized with momentum and knowledge that will define an important road map for organoid-specific standards,” said Dr. Anthony Atala, director of the Wake Forest Institute for Regenerative Medicine and RegMIC board member.

Special announcement from ARPA-H

The RegMIC conference was proud to feature the first public announcement of a new program at ARPA-H.

Gloria Elliott, PhD, program manager at ARPA-H and one of RegMIC’s expert speakers, announced the BioStabilization Systems (BoSS) program. The goal of the program is to develop new technologies to produce, store, and ship cell therapies at room temperature, removing the need for an expensive and fragile cold chain.

Elliott said ARPA-H chose to announce the new program at RegMIC because of the expertise and diversity of fellow speakers and attendees.

“To achieve the goals of the BoSS program, we will need to bring together a diverse and deeply experienced community of innovators from across academia and industry,” she said. “Connecting with teams that are already collaborating on complex, multi-stakeholder challenges that impact American biomanufacturing is a powerful accelerator and vital to our success.” 

Interested in getting involved with defining organoid and body-on-a-chip standards? Email management@remdo.org.

About RegMIC: RegMIC is an industry-led organization dedicated to accelerating the development and commercialization of regenerative medicine therapies. The organization convenes industry leaders, researchers, and innovators to address critical challenges and advance the field. For more information, visit https://remdo.com/regmic/.

About ReMDO:  The RegenMed Development Organization (ReMDO) is a 501(c)3 non-profit with a mission to help deliver on the promise of regenerative medicine by advancing research to de-risk technologies, promoting progress of biomanufacturing scale-up and automation to make technologies more affordable, and speeding up the translation to clinical practice. For more information, visit https://remdo.org/.